David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

Scholar Rock said regulatory submissions for apitegromab in the U.S. and Europe are planned for the first quarter of next year, setting the stage for a potential fourth quarter 2025 commercial launch.

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.

Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...

The biotech company Scholar Rock reported Monday that its experimental medicine improved motor function in patients with a muscle-wasting disease called spinal muscular atrophy, paving the way for ...

Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.